Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Waldenstrom Macroglobulinemia 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Tumor Lysis Syndrome 1Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Azacitidine 38Cytarabine 22venetoclax 19fludarabine phosphate 18fludarabine 18Cyclophosphamide 18Peripheral Blood Stem Cell Transplantation 15Tacrolimus 14Filgrastim 13Decitabine 13Mycophenolic Acid 12Busulfan 12Whole-Body Irradiation 11Melphalan 11Methotrexate 10Cyclosporine 10Antilymphocyte Serum 8Stem Cell Transplantation 7Alemtuzumab 7decitabine and cedazuridine drug combination 6Granulocyte Colony-Stimulating Factor 6Clofarabine 6AP 1903 reagent 6Thiotepa 5Rituximab 5Idarubicin 5quizartinib 4Tretinoin 4Sirolimus 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Myelodysplastic Syndromes × alvocidib × Clear all
NCT03593915 2023-11-09

A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

Sumitomo Pharma America, Inc.

Phase 1/2 Terminated
20 enrolled 13 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡